About xencor inc - XNCR
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
XNCR At a Glance
Xencor, Inc.
465 North Halstead Street
Pasadena, California 91016
| Phone | 1-626-305-5900 | Revenue | 125.58M | |
| Industry | Biotechnology | Net Income | -91,923,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 13.651% | |
| Fiscal Year-end | 12 / 2026 | Employees | 260 | |
| View SEC Filings |
XNCR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.051 |
| Price to Book Ratio | 1.731 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.651 |
| Enterprise Value to Sales | 6.184 |
| Total Debt to Enterprise Value | 0.242 |
XNCR Efficiency
| Revenue/Employee | 482,984.615 |
| Income Per Employee | -353,550.00 |
| Receivables Turnover | 4.286 |
| Total Asset Turnover | 0.137 |
XNCR Liquidity
| Current Ratio | 6.254 |
| Quick Ratio | 6.254 |
| Cash Ratio | 5.711 |
XNCR Profitability
| Gross Margin | 91.629 |
| Operating Margin | -141.35 |
| Pretax Margin | -71.377 |
| Net Margin | -73.201 |
| Return on Assets | -10.06 |
| Return on Equity | -14.00 |
| Return on Total Capital | -11.165 |
| Return on Invested Capital | -11.245 |
XNCR Capital Structure
| Total Debt to Total Equity | 29.539 |
| Total Debt to Total Capital | 22.803 |
| Total Debt to Total Assets | 21.445 |
| Long-Term Debt to Equity | 22.218 |
| Long-Term Debt to Total Capital | 17.152 |